<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ARegulatory_due_diligence</id>
	<title>Definition:Regulatory due diligence - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ARegulatory_due_diligence"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_due_diligence&amp;action=history"/>
	<updated>2026-04-30T11:04:59Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_due_diligence&amp;diff=17777&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Regulatory_due_diligence&amp;diff=17777&amp;oldid=prev"/>
		<updated>2026-03-15T15:38:21Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;🔎 &amp;#039;&amp;#039;&amp;#039;Regulatory due diligence&amp;#039;&amp;#039;&amp;#039; is the investigative workstream within an insurance [[Definition:Mergers and acquisitions (M&amp;amp;A) | transaction]] that examines the target&amp;#039;s compliance with applicable [[Definition:Insurance regulator | insurance regulatory]] requirements, the status of its [[Definition:Insurance license | licenses]] and authorizations, its supervisory history, and the regulatory implications of the proposed deal for both buyer and target. Given that [[Definition:Insurance carrier | insurance companies]] operate under some of the most intensive supervisory regimes of any financial sector — with requirements spanning [[Definition:Solvency II | solvency]], [[Definition:Conduct risk | conduct]], [[Definition:Anti-money laundering (AML) | anti-money laundering]], and governance — regulatory due diligence often determines whether a transaction can proceed at all, and on what terms.&lt;br /&gt;
&lt;br /&gt;
⚙️ The scope typically encompasses several core areas: verification that the target holds valid licenses in every jurisdiction where it writes or services business; review of all correspondence with supervisory authorities, including any [[Definition:Regulatory action | enforcement actions]], supervisory letters, or remediation plans; assessment of compliance with [[Definition:Risk-based capital (RBC) | capital adequacy]] requirements (whether under [[Definition:Solvency II | Solvency II]], the [[Definition:National Association of Insurance Commissioners (NAIC) | NAIC]] RBC framework, [[Definition:C-ROSS | C-ROSS]], or other local regimes); analysis of [[Definition:Fit and proper requirements | fit and proper]] approvals for directors and key function holders; and evaluation of the [[Definition:Regulatory change of control approval | change of control approval]] pathway. For targets that operate as [[Definition:Managing general agent (MGA) | MGAs]] or [[Definition:Coverholder | coverholders]], the review extends to [[Definition:Delegated underwriting authority (DUA) | delegated authority]] arrangements and the regulatory status of those agreements in each relevant market. The diligence team — usually comprising specialist insurance regulatory lawyers in each jurisdiction, supplemented by compliance consultants — works from materials in the [[Definition:Virtual data room (VDR) | data room]] and the [[Definition:Q&amp;amp;A log (questions and answers log) | Q&amp;amp;A log]], and may also conduct direct inquiries with regulators where permitted.&lt;br /&gt;
&lt;br /&gt;
💡 Regulatory due diligence findings can reshape a deal&amp;#039;s structure, pricing, and risk allocation in fundamental ways. Discovery that a target has been operating without a required license in a given market, or that it faces a pending supervisory investigation into [[Definition:Claims management | claims handling]] practices, can trigger [[Definition:Purchase price reduction | purchase price reductions]], enhanced [[Definition:Indemnity | indemnity]] protections, or even deal termination. In cross-border insurance transactions, the complexity multiplies: an acquirer purchasing an insurer with subsidiaries in the EU, the U.S., and Asia must navigate overlapping and sometimes conflicting regulatory expectations. The findings feed into the [[Definition:Regulatory due diligence report | regulatory due diligence report]] and directly inform the [[Definition:Regulatory approval application | regulatory approval application]] strategy, making this workstream one of the highest-priority threads in any insurance deal process.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Regulatory due diligence report]]&lt;br /&gt;
* [[Definition:Due diligence]]&lt;br /&gt;
* [[Definition:Regulatory change of control approval]]&lt;br /&gt;
* [[Definition:Insurance license]]&lt;br /&gt;
* [[Definition:Insurance regulator]]&lt;br /&gt;
* [[Definition:Conduct risk]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>